Cargando…

Recovery of Tenofovir-induced Nephrotoxicity following Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Human Immunodeficiency Virus-Positive Patients

BACKGROUND: Tenofovir disoproxil fumarate (TDF)-induced nephrotoxicity is related to high plasma tenofovir concentrations. Tenofovir alafenamide (TAF) is a tenofovir prodrug with 90% lower plasma tenofovir concentrations. The aim of this study was to evaluate changes in tenofovir-induced nephrotoxic...

Descripción completa

Detalles Bibliográficos
Autores principales: Seo, Jun-Won, Kim, Kichun, Jun, Kang Il, Kang, Chang Kyung, Moon, Song Mi, Song, Kyoung-Ho, Bang, Ji-Hwan, Kim, Eu Suk, Kim, Hong Bin, Park, Sang Won, Kim, Nam Joong, Choe, Pyoeng Gyun, Park, Wan Beom, Oh, Myoung-don
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Infectious Diseases and Korean Society for Chemotherapy 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533205/
https://www.ncbi.nlm.nih.gov/pubmed/32757496
http://dx.doi.org/10.3947/ic.2020.52.3.381
_version_ 1783590080272662528
author Seo, Jun-Won
Kim, Kichun
Jun, Kang Il
Kang, Chang Kyung
Moon, Song Mi
Song, Kyoung-Ho
Bang, Ji-Hwan
Kim, Eu Suk
Kim, Hong Bin
Park, Sang Won
Kim, Nam Joong
Choe, Pyoeng Gyun
Park, Wan Beom
Oh, Myoung-don
author_facet Seo, Jun-Won
Kim, Kichun
Jun, Kang Il
Kang, Chang Kyung
Moon, Song Mi
Song, Kyoung-Ho
Bang, Ji-Hwan
Kim, Eu Suk
Kim, Hong Bin
Park, Sang Won
Kim, Nam Joong
Choe, Pyoeng Gyun
Park, Wan Beom
Oh, Myoung-don
author_sort Seo, Jun-Won
collection PubMed
description BACKGROUND: Tenofovir disoproxil fumarate (TDF)-induced nephrotoxicity is related to high plasma tenofovir concentrations. Tenofovir alafenamide (TAF) is a tenofovir prodrug with 90% lower plasma tenofovir concentrations. The aim of this study was to evaluate changes in tenofovir-induced nephrotoxicity in Human Immunodeficiency Virus (HIV)-positive patients who switched from TDF to TAF. MATERIALS AND METHODS: We identified all HIV-positive patients who switched from elvitegravir/cobicistat/emtricitabine/TDF to elvitegravir/cobicistat/emtricitabine/TAF at a tertiary hospital. We assessed tubulopathy and renal dysfunction before TDF administration, at the time TAF was used following at least 3 months of TDF use, and 3 months after TAF administration. Tubulopathy was defined by the presence of at least three abnormalities in fractional excretion of phosphate, fractional excretion of uric acid, urinary β2-microglobulin, urinary N-acetyl-β-D-glucosaminidase, glucosuria or proteinuria. Renal dysfunction was defined as decreased by more than 25% in the estimated glomerular filtration rate (eGFR) relative to baseline. RESULTS: In 80 patients, the mean eGFR was 96.8 mL/min/1.73 m(2) before administration of TDF, 81.2 (P <0.001) at the time of change to TAF, 90.9 (P <0.001) after TAF administration. Renal dysfunction occurred in 19 patients (23.8%) after TDF use for a median 15 months, 11 (57.9%) of these patients recovered from renal dysfunction after TAF administration. Six patients (7.5%) had tubulopathy before TDF administration, 36 (45.0%) after TDF administration (P <0.001), 12 (15.0%) after TAF administration (P = 0.002). CONCLUSION: Tenofovir-induced nephrotoxicity in HIV-positive patients receiving TDF was mostly reversible after changing to TAF. Thus, TAF-containing regimens can be administered safely to HIV-positive patients with tenofovir-induced nephrotoxicity.
format Online
Article
Text
id pubmed-7533205
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Korean Society of Infectious Diseases and Korean Society for Chemotherapy
record_format MEDLINE/PubMed
spelling pubmed-75332052020-10-13 Recovery of Tenofovir-induced Nephrotoxicity following Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Human Immunodeficiency Virus-Positive Patients Seo, Jun-Won Kim, Kichun Jun, Kang Il Kang, Chang Kyung Moon, Song Mi Song, Kyoung-Ho Bang, Ji-Hwan Kim, Eu Suk Kim, Hong Bin Park, Sang Won Kim, Nam Joong Choe, Pyoeng Gyun Park, Wan Beom Oh, Myoung-don Infect Chemother Original Article BACKGROUND: Tenofovir disoproxil fumarate (TDF)-induced nephrotoxicity is related to high plasma tenofovir concentrations. Tenofovir alafenamide (TAF) is a tenofovir prodrug with 90% lower plasma tenofovir concentrations. The aim of this study was to evaluate changes in tenofovir-induced nephrotoxicity in Human Immunodeficiency Virus (HIV)-positive patients who switched from TDF to TAF. MATERIALS AND METHODS: We identified all HIV-positive patients who switched from elvitegravir/cobicistat/emtricitabine/TDF to elvitegravir/cobicistat/emtricitabine/TAF at a tertiary hospital. We assessed tubulopathy and renal dysfunction before TDF administration, at the time TAF was used following at least 3 months of TDF use, and 3 months after TAF administration. Tubulopathy was defined by the presence of at least three abnormalities in fractional excretion of phosphate, fractional excretion of uric acid, urinary β2-microglobulin, urinary N-acetyl-β-D-glucosaminidase, glucosuria or proteinuria. Renal dysfunction was defined as decreased by more than 25% in the estimated glomerular filtration rate (eGFR) relative to baseline. RESULTS: In 80 patients, the mean eGFR was 96.8 mL/min/1.73 m(2) before administration of TDF, 81.2 (P <0.001) at the time of change to TAF, 90.9 (P <0.001) after TAF administration. Renal dysfunction occurred in 19 patients (23.8%) after TDF use for a median 15 months, 11 (57.9%) of these patients recovered from renal dysfunction after TAF administration. Six patients (7.5%) had tubulopathy before TDF administration, 36 (45.0%) after TDF administration (P <0.001), 12 (15.0%) after TAF administration (P = 0.002). CONCLUSION: Tenofovir-induced nephrotoxicity in HIV-positive patients receiving TDF was mostly reversible after changing to TAF. Thus, TAF-containing regimens can be administered safely to HIV-positive patients with tenofovir-induced nephrotoxicity. The Korean Society of Infectious Diseases and Korean Society for Chemotherapy 2020-09 2020-07-16 /pmc/articles/PMC7533205/ /pubmed/32757496 http://dx.doi.org/10.3947/ic.2020.52.3.381 Text en Copyright © 2020 by The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, and The Korean Society for AIDS https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Seo, Jun-Won
Kim, Kichun
Jun, Kang Il
Kang, Chang Kyung
Moon, Song Mi
Song, Kyoung-Ho
Bang, Ji-Hwan
Kim, Eu Suk
Kim, Hong Bin
Park, Sang Won
Kim, Nam Joong
Choe, Pyoeng Gyun
Park, Wan Beom
Oh, Myoung-don
Recovery of Tenofovir-induced Nephrotoxicity following Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Human Immunodeficiency Virus-Positive Patients
title Recovery of Tenofovir-induced Nephrotoxicity following Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Human Immunodeficiency Virus-Positive Patients
title_full Recovery of Tenofovir-induced Nephrotoxicity following Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Human Immunodeficiency Virus-Positive Patients
title_fullStr Recovery of Tenofovir-induced Nephrotoxicity following Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Human Immunodeficiency Virus-Positive Patients
title_full_unstemmed Recovery of Tenofovir-induced Nephrotoxicity following Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Human Immunodeficiency Virus-Positive Patients
title_short Recovery of Tenofovir-induced Nephrotoxicity following Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Human Immunodeficiency Virus-Positive Patients
title_sort recovery of tenofovir-induced nephrotoxicity following switch from tenofovir disoproxil fumarate to tenofovir alafenamide in human immunodeficiency virus-positive patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533205/
https://www.ncbi.nlm.nih.gov/pubmed/32757496
http://dx.doi.org/10.3947/ic.2020.52.3.381
work_keys_str_mv AT seojunwon recoveryoftenofovirinducednephrotoxicityfollowingswitchfromtenofovirdisoproxilfumaratetotenofoviralafenamideinhumanimmunodeficiencyviruspositivepatients
AT kimkichun recoveryoftenofovirinducednephrotoxicityfollowingswitchfromtenofovirdisoproxilfumaratetotenofoviralafenamideinhumanimmunodeficiencyviruspositivepatients
AT junkangil recoveryoftenofovirinducednephrotoxicityfollowingswitchfromtenofovirdisoproxilfumaratetotenofoviralafenamideinhumanimmunodeficiencyviruspositivepatients
AT kangchangkyung recoveryoftenofovirinducednephrotoxicityfollowingswitchfromtenofovirdisoproxilfumaratetotenofoviralafenamideinhumanimmunodeficiencyviruspositivepatients
AT moonsongmi recoveryoftenofovirinducednephrotoxicityfollowingswitchfromtenofovirdisoproxilfumaratetotenofoviralafenamideinhumanimmunodeficiencyviruspositivepatients
AT songkyoungho recoveryoftenofovirinducednephrotoxicityfollowingswitchfromtenofovirdisoproxilfumaratetotenofoviralafenamideinhumanimmunodeficiencyviruspositivepatients
AT bangjihwan recoveryoftenofovirinducednephrotoxicityfollowingswitchfromtenofovirdisoproxilfumaratetotenofoviralafenamideinhumanimmunodeficiencyviruspositivepatients
AT kimeusuk recoveryoftenofovirinducednephrotoxicityfollowingswitchfromtenofovirdisoproxilfumaratetotenofoviralafenamideinhumanimmunodeficiencyviruspositivepatients
AT kimhongbin recoveryoftenofovirinducednephrotoxicityfollowingswitchfromtenofovirdisoproxilfumaratetotenofoviralafenamideinhumanimmunodeficiencyviruspositivepatients
AT parksangwon recoveryoftenofovirinducednephrotoxicityfollowingswitchfromtenofovirdisoproxilfumaratetotenofoviralafenamideinhumanimmunodeficiencyviruspositivepatients
AT kimnamjoong recoveryoftenofovirinducednephrotoxicityfollowingswitchfromtenofovirdisoproxilfumaratetotenofoviralafenamideinhumanimmunodeficiencyviruspositivepatients
AT choepyoenggyun recoveryoftenofovirinducednephrotoxicityfollowingswitchfromtenofovirdisoproxilfumaratetotenofoviralafenamideinhumanimmunodeficiencyviruspositivepatients
AT parkwanbeom recoveryoftenofovirinducednephrotoxicityfollowingswitchfromtenofovirdisoproxilfumaratetotenofoviralafenamideinhumanimmunodeficiencyviruspositivepatients
AT ohmyoungdon recoveryoftenofovirinducednephrotoxicityfollowingswitchfromtenofovirdisoproxilfumaratetotenofoviralafenamideinhumanimmunodeficiencyviruspositivepatients